62nd ASH Annual Meeting and Exposition: 802. Chemical Biology and Experimental Therapeutics: Innovations in Therapy and Drug Screening

Oral and Poster Abstracts
Oral

AML, Adult, Leukemia, ALL, Biological, antibodies, apoptosis, HSCs, Diseases, Non-Biological, CLL, Lymphoma (any), Combinations, CAR-Ts, Therapies, cell regulation, Elderly, chemotherapy, Non-Hodgkin Lymphoma, cellular interactions, Pediatric, Biological Processes, enzyme inhibitors, Technology and Procedures, Xenograft models, immunotherapy, Cell Lineage, cytogenetics, Study Population, Lymphoid Malignancies, Myeloid Malignancies, Clinically relevant, genomics, genetic profiling, immune mechanism, flow cytometry, TKI, inflammation, integrative -omics, molecular testing, stem cells, NGS, metabolomics, microenvironment, RNA sequencing, pathways, proteomics, signal transduction

Moderators:

Cristina E. Tognon, PhD, Oregon Health & Science University and Krister Wennerberg, PhD, University of Copenhagen

Disclosures:

No relevant conflicts of interest to declare.

7:00 AM

565

Proteogenomic Subtyping of Chronic Lymphocytic Leukemia Identifies a Novel Poor Outcome Subgroup with a Distinct Drug Response Profile

Sophie A. Herbst, PhD^1,2,3,4,5^*, Mattias Vesterlund⁶^*, Rozbeh Jafari, PhD⁶^*, Ioannis Siavelis⁶^*, Matthias Stahl⁶^*, Eva Schitter¹^*, Alexander J. Helmboldt³^*, Murat Iskar⁷^*, Nora Liebers, MD^1,2,3,4^*, Felix Czernilofsky¹^*, Tobias Roider, MD^1,2,3^*, Peter-Martin Bruch^1,2,3,5^*, Junyan Lu³^*, Sarah Richter¹^*, Georgios Mermelekas⁶^*, Husen Muhammad Umer⁶^*, Mareike Knoll¹^*, Carolin Kolb¹^*, Angela Lenze¹^*, Xiaofang Cao⁶^*, Cecilia Österholm-Corbascio⁸^*, Sebastian Scheinost⁴^*, Matthias Ganzinger⁹^*, Larry Mansouri, PhD⁸^*, Katharina Kriegsmann, MD¹^*, Mark Kriegsmann, MD¹⁰^*, Carsten Mueller-Tidow, MD^1,2,3^*, Peter Dreger, MD¹, Simon Anders, PhD¹¹^*, Marc Zapatka⁷^*, Marco Herling, MD^12,13^*, Richard Rosenquist, MD⁸, Stephan Stilgenbauer, MD¹⁴, Thorsten Zenz^4,15, Wolfgang Huber, PhD^2,3^*, Eugen Tausch, MD¹⁶^*, Janne Lehtiö⁶^* and Sascha Dietrich, M.D.^1,2,3,4

¹Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany
²Molecular Medicine Partnership Unit (MMPU), Heidelberg, Germany
³European Molecular Biology Laboratory (EMBL), Heidelberg, Germany
⁴National Center for Tumor Diseases Heidelberg, Heidelberg, Germany
⁵University of Heidelberg, Heidelberg, Germany
⁶Oncology-Pathology, Science for Life Laboratory, Karolinska Institutet, Stockholm, Sweden
⁷Division of Molecular Genetics, German Cancer Research Center (DKFZ), Heidelberg, Germany
⁸Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden
⁹Institute of Medical Biometry and Informatics, Heidelberg University, Heidelberg, Germany
¹⁰Institute of Pathology, Heidelberg University, Heidelberg, Germany
¹¹Center for Molecular Biology of University of Heidelberg (ZMBH), University of Heidelberg, Heidelberg, Germany
¹²Department I of Internal Medicine, Center for Integrated Oncology Aachen-Bonn-Cologne-Duesseldorf (CIO ABCD), Cologne, Germany
¹³Excellence Cluster for Cellular Stress Response and Aging-Associated Diseases (CECAD), Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany
¹⁴Department of Internal Medicine III, University Hospital Ulm, Ulm, Germany
¹⁵Medical Oncology and Haematology, University Hospital Zürich, Zürich, Switzerland
¹⁶Department of Internal Medicine III, Ulm University, Ulm, Germany

7:15 AM

566

Generation of Multiplexed Engineered, Off-the-Shelf CAR T Cells Uniformly Carrying Multiple Anti-Tumor Modalities to Prevent Tumor Relapse

Chiawei Chang¹^*, Eigen Peralta, PhD¹^*, Gloria Hsia, PhD¹^*, Bi-Huei Yang, PhD¹^*, Wen-I Yeh, PhD¹^*, Raedun Clarke, PhD¹^*, Mandal Mili, PhD¹^*, Tom Lee, PhD²^*, Mochtar Pribadi, PhD¹^*, Ramzey Abujarour, PhD¹^*, Yi-Shin Lai, PhD¹^*, David Robbins, BS²^*, Matthew Denholtz, PhD¹^*, Sandeep Kothapally Hanok²^*, Emily Driver, BS¹^*, Emily Carron, PhD²^*, Natalie Navarrete, BS²^*, May Sumi¹^*, Amit Mehta¹^*, Philip Chu¹^*, Jason ORourke, PhD²^*, Alma Gutierrez¹^*, Eric Sung²^*, Suzanna Gasparian¹^*, Angela Gentile²^*, Alec Witty, PhD¹^*, Amanda Yzaguirre¹^*, Samuel LaBarge¹^*, Cokey Nguyen, PhD¹^* and Bahram Valamehr, PhD²

¹Fate Therapeutics Inc., San Diego, CA
²Fate Therapeutics, Inc., San Diego, CA

7:30 AM

567

A Functional Profiling of Microenvironmental Factors and Small Molecules Reveals Monocyte Chemoattractant Protein-1 Mediates Drug Resistance in Acute Myeloid Leukemia

Rucha V Modak, PhD¹^*, Sara J Gosline²^*, Alisa Damnernsawad, PhD³, Tamilla Nechiporuk, PhD⁴^*, Ted Laderas, PhD⁵^*, Guanming Wu, PhD⁶^*, Paul Piehowski, Paul.Piehowski@pnnl.gov²^*, Stephen E Kurtz, PhD⁷^*, Christopher A. Eide⁸^*, Jeffrey W. Tyner, PhD⁷, Karin Rodland, rodland@ohsu.edu^2,6^*, Shannon K. McWeeney, PhD⁵^* and Anupriya Agarwal, PhD⁷

¹Division of Hematology and Medical Oncology, Oregon Health and Science University, PORTLAND, OR
²Pacific Northwest National Laboratory, Richland, WA
³Knight Cancer Institute, Oregon Health & Science University, Hillsboro, OR
⁴Division of Hematology & Medical Oncology, Oregon Health & Science University, Portland, OR
⁵Division of Bioinformatics and Computational Biology, Oregon Health & Science University, Portland, OR
⁶Oregon Health & Science University, Portland, OR
⁷Knight Cancer Institute, Division of Hematology & Medical Oncology, Oregon Health & Science University, Portland, OR
⁸Knight Cancer Institute, Oregon Health & Science University, Portland, OR

7:45 AM

568

Niche-like Ex Vivo High Throughput (NEXT) Drug Screening Platform in Acute Myeloid Leukemia

Reinaldo Dal Bello, MD^1,2,3, Justine Pasanisi⁴^*, Romane Joudinaud⁵^*, Matthieu Duchmann⁶^*, Gaetano Sodaro⁷^*, Clementine Chauvel⁵^*, Loic Vasseur, MD⁸^*, Bryann Pardieu⁵^*, Frank Ling⁷^*, Kim Pacchiardi⁹^*, Camille Vaganay⁵^*, Lionel Faivre⁹^*, Chaïma Benaksas⁵^*, Claude Preudhomme, MD, PhD¹⁰, Emmanuel Raffoux, MD¹¹^*, Emmanuelle Clappier, PhD, PharmD¹²^*, Lionel Ades, MD, PhD¹³, Alexandre Puissant, PhD¹⁴^* and Raphael Itzykson, MD, PhD¹⁵

¹INSERM, INSERM U944, Institut Universitaire d'Hématologie, Hôpital Saint-Louis, Paris, France
²Hematology Department, Instituto Nacional do Câncer, Rio de Janeiro, Brazil
³Hematology Department, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil
⁴Hematology Laboratory and INSERM U944, Hopital Saint-Louis, Paris, France
⁵INSERM, Université de Paris, Paris, France
⁶St Louis Hospital, Hematology Laboratory, Paris, France
⁷INSERM U944, St Louis Hospital, PARIS, France
⁸Hopital Saint-Louis, AP-HP, Paris, France
⁹Hôpital Saint Louis, Paris, France
¹⁰Centre de Biologie-Pathologie, CHU Lille, Lille, France
¹¹Hématologie clinique, Hôpital Saint-Louis, Paris, France
¹²Hematology Laboratory, Saint Louis Hospital, AP-HP, Paris, France
¹³Institut Univeristaire d'Hematologie, Hopital Saint Louis, Paris, France
¹⁴APHP, INSERM U944, Institute of Hematology - St Louis Hospital, PARIS, France
¹⁵Hematology Department, Saint-Louis Hospital AP-HP Paris France, Paris, France

8:00 AM

569

Targeting Oncoproteins with a Positive Selection Assay for Protein Degraders

Sagar Koduri, MD, PhD¹, Adam C. Wang, B.S.²^*, Mette Ishoey, PhD³^*, Joshiawa Paulk³^*, Xiaoxi Liu, PhD²^*, Isaac Harris, PhD⁴^*, Jennifer Endress, B.S.⁵^*, Benjamin L. Lampson, MD, PhD⁶, Christopher J. Ott, PhD⁷, James Bradner, MD⁸, Jeffrey A. Medin, PhD⁹, Sara J Buhrlage, PhD¹⁰^* and William Kaelin, MD^3,11,12^*

¹Dana Farber Cancer Institute, Brookline, MA
²Dana Farber Cancer Institute, Boston, MA
³Medical Oncology, Dana Farber Cancer Institute, Boston, MA
⁴Harvard Medical School, Boston, MA
⁵Meyer Cancer Center, Weill Cornell Medicine, New York, NY
⁶Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
⁷MGH Cancer Center, Charlestown, MA
⁸Novartis, Boston, MA
⁹Department of Biochemistry, Medical College of Wisconsin, Milwaukee, WI
¹⁰Biological Chemistry & Molecular Pharmacology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
¹¹Howard Hughes Medical Institute, Chevy Chase, MD
¹²Brigham & Women's Hospital, Boston, MA

8:15 AM

570

Phospho-Proteomic Profiling of T-Cell Acute Lymphoblastic Leukemia Identifies Targetable Kinase Activities and Novel Treatment Combination Strategies

Valentina Cordo', MSc¹^*, Rico Hagelaar¹^*, Sander Piersma²^*, Richard Goeij-de Haas²^*, Thang V Pham²^*, Jelle Dylus³^*, Guido Zaman, PhD³^*, Connie Jimenez, PhD²^* and Jules P.P. Meijerink, PhD¹

¹Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands
²Proteomics facility, Amsterdam UMC, VU University Medical Center, Cancer Centre Amsterdam, Amsterdam, Netherlands
³Netherlands Translational Research Center, Oss, Netherlands

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

802.O1.6 802. Chemical Biology and Experimental Therapeutics: Innovations in Therapy and Drug Screening